630,840 Shares in Elanco Animal Health Incorporated $ELAN Acquired by Hardman Johnston Global Advisors LLC

Key Points

• Hardman Johnston Global Advisors LLC purchased a new position of 630,840 shares (~$14.28M) in Elanco Animal Health, representing about 0.13% of the company at the end of the quarter.
• Institutional investors own roughly 97.48% of ELAN, with large funds such as UBS, Goldman Sachs, Dimensional and Jupiter materially increasing their stakes in recent quarters.
• Analysts hold a consensus "Moderate Buy" with a target price of $27.67; Elanco recently beat quarterly EPS and revenue estimates and issued FY2026 guidance of 1.00–1.06 EPS.

Hardman Johnston Global Advisors LLC purchased a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 630,840 shares of the company's stock, valued at approximately $14,276,000. Hardman Johnston Global Advisors LLC owned about 0.13% of Elanco Animal Health at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of ELAN. UBS Group AG raised its stake in shares of Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company's stock worth $331,669,000 after buying an additional 5,961,457 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock valued at $50,268,000 after purchasing an additional 2,445,872 shares during the period. Bowen Hanes & Co. Inc. acquired a new position in Elanco Animal Health during the third quarter valued at approximately $47,626,000. Dimensional Fund Advisors LP grew its holdings in Elanco Animal Health by 8.6% during the third quarter. Dimensional Fund Advisors LP now owns 24,708,676 shares of the company's stock valued at $497,610,000 after purchasing an additional 1,962,276 shares during the period. Finally, Jupiter Asset Management Ltd. grew its holdings in Elanco Animal Health by 98.8% during the third quarter. Jupiter Asset Management Ltd. now owns 3,716,849 shares of the company's stock valued at $74,857,000 after purchasing an additional 1,846,907 shares during the period. 97.48% of the stock is owned by institutional investors.

Analyst Ratings Changes

ELAN has been the subject of a number of analyst reports. KeyCorp boosted their price objective on shares of Elanco Animal Health from $27.00 to $29.00 and gave the company an "overweight" rating in a report on Wednesday, February 25th. Weiss Ratings restated a "sell (d+)" rating on shares of Elanco Animal Health in a report on Friday, March 27th. JPMorgan Chase & Co. boosted their price objective on shares of Elanco Animal Health from $24.00 to $28.00 and gave the company an "overweight" rating in a report on Thursday, February 19th. UBS Group restated a "buy" rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. Finally, Morgan Stanley boosted their price objective on shares of Elanco Animal Health from $22.00 to $24.00 and gave the company an "equal weight" rating in a report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Elanco Animal Health currently has a consensus rating of "Moderate Buy" and a consensus target price of $27.67.

Elanco Animal Health Stock Down 0.1%

Elanco Animal Health stock opened at $23.11 on Monday. The stock has a market capitalization of $11.49 billion, a PE ratio of -48.14, a price-to-earnings-growth ratio of 2.95 and a beta of 1.88. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $27.72. The company has a quick ratio of 1.08, a current ratio of 2.17 and a debt-to-equity ratio of 0.60. The company has a 50 day moving average of $24.44 and a 200-day moving average of $23.00.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02. The company had revenue of $1.14 billion during the quarter, compared to analysts' expectations of $1.09 billion. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The business's quarterly revenue was up 12.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.14 earnings per share. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. On average, equities research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.